Blood cancers

Australian trial reveals tocilizumab effect in acute GVHD

Hopes that the immunosuppressive drug tocilizumab would help improves outcomes for acute GVHD in patients undergoing allogeneic SCT have been dashed by an Australian study. While the interleukin-6 inhibitor showed a trend towards benefit when used in volunteer-unrelated-donors, it not significantly reduce the incidence of grade II-IV acute GVHD, a phase 3 randomised controlled trial ...

Already a member?

Login to keep reading.

© 2021 the limbic